Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study

Table 3 Favorable response to micafungin therapy in different subgroups

Subgroups	Favorable response %, (n)	Relative Risk (95% CI)	p
Total
(n = 104/108, missing = 4)	67 (70/104)
Type of IC			0.77
Proven IC	66 (37/56)	1 (ref)
Suspected IC	69 (33/48)	1.04 (0.80 - 1.36)
Therapy			0.32
Monotherapy	69 (65/94)	1 (ref)
Combined therapy^†	50 (5/10)	0.72 (0.38 - 1.36)
Age			0.14
Patients < 18 years	76 (26/34)	1 (ref)
Patients ≥ 18 years	63 (44/70)	0.82 (0.63 - 1.06)
Pathogen			0.76
C. albicans	68 (23/34)	1 (ref)
Non-albicans Candida spp.*	64 (14/22)	0.94 (0.64 - 1.39)
Recent surgery			0.47
Yes	60 (12/20)	1 (ref)
No	69 (58/84)	1.15 (0.78 - 1.69)
Neutropenia (missing = 6)			0.38
ANC < 500/mm³	76 (13/17)	1 (ref)
ANC ≥ 500/mm³	67 (54/81)	0.87 (0.64 - 1.18)
Active malignancy			0.66
Yes**	71 (17/24)	1 (ref)
No	66 (53/80)	0.95 (0.69 - 1.26)
Allogeneic HSCT			0.75
Yes	60 (3/5)	1 (ref)
No	68 (67/99)	1.13 (0.54 - 2.34)
Ward			0.18
ICU/NICU	57 (17/30)	1 (ref)
Non-ICU/NICU	72 (53/74)	1.26 (0.89 - 1.78)

IC, invasive candidiasis; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit; NICU, neonatal intensive care unit; ANC, absolute neutrophil count.
^†lipid formulations of amphotericin B (8/10, 80%), voriconazole (1/10, 10%), and fluconazole (1/10, 10%).
*C. parapsilosis 6/8 (75%), C. glabrata 4/7 (57%), other Candida spp. or polymicrobial 4/7 (57%).
**Hematological (n = 9) or solid (n = 8) neoplasms.

ISSN: 1471-2334